1705-16-4

Basic information

• Product Name: 3-trifluoromethylbutyrophenone
• Synonyms: 3-trifluoromethylbutyrophenone;1-(3-trifluoromethylphenyl)butan-1-one
• CAS NO: 1705-16-4
• Molecular Formula: C₁₁H₁₁F₃O
• Molecular Weight: 216.1996496
• Mol File: 1705-16-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 138-140 °C(Press: 20 Torr)
• Appearance: /
• Density: 1.153±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 3-trifluoromethylbutyrophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-trifluoromethylbutyrophenone(1705-16-4)
• EPA Substance Registry System: 3-trifluoromethylbutyrophenone(1705-16-4)

Safety Data

• Hazardous Substances Data: 1705-16-4(Hazardous Substances Data)

Usage

General Description

3-Trifluoromethylbutyrophenone is a chemical compound with the chemical formula C13H11F3O. It is a potent dopamine antagonist and has been used in scientific research as a tool to study the effects of dopamine activity in the brain. It is also a potential candidate for the development of new medications for neurological and psychiatric disorders, as it may modulate dopamine receptors. Additionally, 3-trifluoromethylbutyrophenone has been investigated for its potential antipsychotic and sedative effects, and may have a role in the treatment of conditions such as schizophrenia and bipolar disorder. However, further research is needed to fully understand its pharmacological properties and potential therapeutic applications.

Upstream product

• 454-92-2 3-(trifluoromethyl)benzoic acid 
• 368-77-4 3-trifluoromethylbenzonitrile 

Downstream Products

• 1238892-13-1 1-methoxy-2-((3-(trifluoromethyl)phenyl)ethynyl)benzene 
• 325142-82-3 4,4,5,5-tetramethyl-2-(3-(trifluoromethyl)phenyl)-1,3,2-dioxaborolane 

Relevant articles and documents

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

Synthesis and evaluation of the anticonvulsant activity of a series of 2-amino-1-phenyl-1-propranols derived from the metabolites of the antidepressant bupropion

A series of 2-amino-1-phenyl-1-propanols that are structurally related to known metabolites of bupropion, 1 (Wellbutrin) were synthesized and evaluated as potential anticonvulsants. The (R*,R*)-2-tert-butylamino-1-(3-trifluoromethylphenyl) propanol 20 had an ED50 of 16.5 ± 2.8 mg/kg ip in mice in the maximal electroshock screen and was chosen for further evaluation.